Latest Breaking News On - Leslie humbel - Page 3 : comparemela.com

Verona Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update

US FDA accepted NDA filing for ensifentrine for maintenance treatment of COPD PDUFA Target Action Date of June 26, 2024 Commercial launch preparations supported by strong balance sheet Conference.

United kingdomUnited statesCity ofVerona pharmaLeslie humbelDavid zaccardelliCedric jamie rutlandChristina ackermannProgram updatesInternational congressLomb corporationEuropean respiratory society international congressOphthalmic pharmaceuticals at bauschBridge communicationsGlobenewswire incInternational us media enquiries

Verona Pharma to Report Third Quarter 2023 Financial Results and Provide Corporate Update

Verona Pharma to Report Third Quarter 2023 Financial Results and Provide Corporate Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesCity ofLeslie humbelVerona pharmaDrug administrationInternational us media enquiriesKingdom telSenior directorInvestor relations

Verona Pharma to Host Investor Update on Commercialization Preparation for Ensifentrine on October 18, 2023

LONDON and RALEIGH, N.C., Oct. 06, 2023 Verona Pharma plc , announces it will hold an Investor Update in New York City for investors and analysts on Wednesday, October 18, 2023, from 8:00 -.

United kingdomNew yorkUnited statesCity ofLeslie humbelCedric jamie rutlandVerona pharmaDrug administrationGlobenewswire incInternational us media enquiriesBridge communicationsInvestor updateYork cityMedical directorWest coast lungNew drug application

Verona Pharma to Host Investor Update on Commercialization

LONDON and RALEIGH, N.C., Oct. 06, 2023 (GLOBE NEWSWIRE) Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces it will hold.

United kingdomNew yorkUnited statesCity ofLeslie humbelCedric jamie rutlandVerona pharmaInternational us media enquiriesDrug administrationInvestor updateNew york cityMedical directorWest coast lungNew drug applicationPrescription drug user fee actKingdom tel

Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at CHEST 2023

PDUFA Target Action Date of June 26, 2024 Pooled analysis and subgroup data further support potential of ensifentrine, an investigational, novel, selective, dual inhibitor of PDE3 and PDE4 LONDON.

United kingdomCity ofVerona pharmaFrank sciurbaLeslie humbelThomas silerDrug administrationUniversity of pittsburgh school medicineGlobenewswire incBridge communicationsInternational us media enquiriesAction dateAssociate professorPittsburgh schoolCritical care medicineLatest advances